ReviewJournal of cancer research and clinical oncology2023
Lessons learned: the first consecutive 1000 patients of the CCCMunich
Review in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 53 citations in OpenAlex.
- Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.International journal of cancer · 2026Article
- Retrospective analysis of real-world clinical use of comprehensive genomic profiling in solid tumors in Finland 2017-2020.ESMO real world data and digital oncology · 2026Article
- Performance and Clinical Benefit of Comprehensive Genomic Profiling of GI Tumors in a Comprehensive Cancer Center.JCO precision oncology · 2026Article
- From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board.Targeted oncology · 2026Article
- Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment.Medical sciences (Basel, Switzerland) · 2026Review
- Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at University Cancer Center Hamburg (2016-2022).The oncologist · 2026Article
- Real-world data on the clinical impact of molecular tumor boards in high- and low-grade serous ovarian cancer.Frontiers in oncology · 2026Article
- Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study.JHEP reports : innovation in hepatology · 2026Article
- Clinical utility and characteristics of comprehensive genomic profiling tests in patients with gynecologic cancer: a multi-institutional survey in Kinki District, Japan.International journal of clinical oncology · 2025Article
- Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?Cancer medicine · 2025Article
- Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichTargeted oncology · 2025Article
- Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients.NPJ precision oncology · 2025Article
- Molecular tumor board in patients with metastatic breast cancer.Breast cancer research and treatment · 2025Article
- The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification.ESMO real world data and digital oncology · 2024Article
- Tumor board simulation improves interdisciplinary decision-making in medical students.Journal of cancer research and clinical oncology · 2024Article
- Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- [Personalized medicine in oncology].Pathologie (Heidelberg, Germany) · 2024Review
- Supporting the decision to perform molecular profiling for cancer patients based on routinely collected data through the use of machine learning.Clinical and experimental medicine · 2024Article
- Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.International journal of molecular sciences · 2024Article
- Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: A scoping review.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn 2016, the University of Munich Molecular Tumor Board (MTB) was implemented to initiate a precision oncology program. This review of cases was conducted to assess clinical implications and functionality of the program, to identify current limitations and to inform future directions of these efforts.
methodsCharts, molecular profiles, and tumor board decisions of the first 1000 consecutive cases (01/2016-03/2020) were reviewed. Descriptive statistics were applied to describe relevant findings.
resultsOf the first 1000 patients presented to the MTB; 914 patients received comprehensive genomic profiling. Median age of patients was 56 years and 58% were female. The most prevalent diagnoses were breast (16%) and colorectal cancer (10%). Different types of targeted or genome-wide sequencing assays were used; most of them offered by the local department of pathology. Testing was technically successful in 88%. In 41% of cases, a genomic alteration triggered a therapeutic recommendation. The fraction of patients receiving a tumor board recommendation differed significantly between malignancies ranging from over 50% in breast or biliary tract to less than 30% in pancreatic cancers. Based on a retrospective chart review, 17% of patients with an MTB recommendation received appropriate treatment.
conclusionBased on these retrospective analyses, patients with certain malignancies (breast and biliary tract cancer) tend to be more likely to have actionable variants. The low rate of therapeutic implementation (17% of patients receiving a tumor board recommendation) underscores the importance of meticulous follow-up for these patients and ensuring broad access to innovative therapies for patients receiving molecular tumor profiling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.